{"nctId":"NCT00638690","briefTitle":"Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy","startDateStruct":{"date":"2008-05"},"conditions":["Prostatic Neoplasms"],"count":1195,"armGroups":[{"label":"Abiraterone acetate plus prednisone/prednisolone","type":"EXPERIMENTAL","interventionNames":["Drug: Abiraterone acetate","Drug: Prednisone/prednisolone"]},{"label":"Placebo plus prednisone/prednisolone","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Prednisone/prednisolone"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Abiraterone acetate","otherNames":[]},{"name":"Prednisone/prednisolone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior cytotoxic chemotherapies\n* At least one chemotherapy must have contained docetaxel\n* Eastern Cooperative Oncology Group (ECOG) Performance Status \\<= 2\n* Medical or surgical castration with testosterone \\< 50 ng/dL\n* Adequate bone marrow, hepatic and renal function\n* Potassium \\>= 3.5 mmol/L\n* Able to swallow the study drug whole as a tablet\n* Informed Consent\n\nExclusion Criteria:\n\n* More than two prior cytotoxic chemotherapy regimens\n* Prior Ketoconazole for prostate cancer\n* Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting the androgen receptor for prostate cancer\n* Uncontrolled hypertension\n* Active or symptomatic viral hepatitis or chronic liver disease\n* History of pituitary or adrenal dysfunction\n* Clinically significant heart disease\n* Other malignancy\n* Known brain metastasis\n* GI disorder affecting absorption\n* Not willing to use contraception","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival is defined as the time interval from the date of randomization to the date of death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"450.0","spread":null},{"groupId":"OG001","value":"332.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria","description":"The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"309.0","spread":null},{"groupId":"OG001","value":"200.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%","description":"A prostate-specific antigen (PSA) response was defined as a \\>=50% decline from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Radiographic Progression-free Survival","description":"Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be \\>=2.0 cm to be considered a target lesion; progression on bone scans with \\>=2 new lesions not consistent with tumor flare, confirmed on a second scan \\>=6 weeks later that shows \\>=1 additional new lesion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171.0","spread":null},{"groupId":"OG001","value":"110.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":365,"n":791},"commonTop":["Fatigue","Back pain","Nausea","Constipation","Arthralgia"]}}}